April 9, 2018

Cleveland Clinic Develops First Overall Risk Prediction Model for Cervical Cancer

Accurate risk prediction reduces costs and false positives

pap-650×450

Thanks to advanced screening technology, no one in the U.S. should die of cervical cancer. But the reality is that thousands of deaths occur each year. The main cause of this phenomena is that high-risk women aren’t being screened often enough or don’t pursue the proper followup when problems are detected.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To improve patient outcomes, physician-researchers are reviewing cervical cancer screening guidelines to look for opportunities for improvement. In particular, they have identified some potential cost benefits associated with making screening recommendations that are based on individual patient risk. Michael Rothberg, MD, Vice Chair for Research in the Medicine Institute at Cleveland Clinic, recently published a ground-breaking risk prediction model to allow for personalized screening for cervical cancer and patient risk assessment.

“While HPV tests are very helpful in predicting cancer risk, other factors are just as powerful at predicting cervical cancer risk,” notes Dr. Rothberg. “The more that we can personalize risk prediction, the more efficient our screening efforts will become.”

Cervical cancer screening guidelines

Doctors used to recommend that women get Pap smears annually to check for cervical abnormalities. Now, the guidelines specify the following screening frequency:

The presence of certain risk factors or abnormal test results may require more frequent testing. The following terms help define cervical cancer and guide treatment:

New model for risk prediction

According to Dr. Rothberg, the following factors may impact a woman’s risk of developing cervical cancer:

Advertisement
  • Smoking (increases risk)
  • Sexual activity (exposure to sexual partners with HPV increases risk)
  • Income (the lower the income, the higher the risk)
  • Age (older women without a history of problematic Pap smears are less likely to develop cervical cancer)

Figure 1: Actual risk observed versus predicted risk of CIN2+ in 100,000 women. The red line represents the risk of CIN2+ in women with ASCUS but who are HPV negative. (Source: Springer/Cleveland Clinic)

Although the above risk factors are well-known in the medical community, no organization had tried to create a model that put these risk factors together to predict a woman’s overall risk of developing cervical cancer. To build the model, Dr. Rothberg worked with Bo Hu, PhD, and Xian Wen Jin, MD, PhD, to analyze data from over 100,000 women who had been screened over a 10-year period at Cleveland Clinic. They identified all patients who had cervical abnormalities.

Dr. Rothberg’s team discovered that a third of the women in the study had a CIN2-level cervical cancer risk below 0.2 percent before they had their Pap smear or HPV test. This is lower than the risk of CIN2+ for a woman who had abnormal cells (ASCUS) detected in her Pap smear but also had a negative HPV test. Yet, this type of patient would wait up to three years to have another co-test, as suggested by the ASCCP guidelines for cervical cancer testing and followup.

Advertisement

“Our study was based on the concept of equal treatment for equal risk,” explains Dr. Rothberg. “We’re hoping to use these known patient factors combined with the last HPV test results from the previous five years to predict the risk of abnormality that would require the patient to have a colposcopy.” The new model could help reduce unnecessary colposcopy tests, which are more uncomfortable and expensive than Pap smears.

Strategic screenings conserve resources

Following his research, Dr. Rothberg suggests that women with a low chance of cervical abnormalities can wait longer to be checked. Why is this so important? “Healthcare resources in the U.S. are limited,” he says. “If unnecessary testing and screening can be eliminated, we can direct the unused resources to target women who are at higher risk of having cervical issues. We can also reduce false positives, which tend to increase with overtesting.”

Tailored prediction models

Dr. Rothberg hopes that his research will help organizations that develop guidelines for cervical cancer screening to create and utilize better prediction models. With the aid of modern electronic data extraction, building future data sets and analyzing the intervals and risk factors of a particular health system would be relatively easy. “Better prediction models that are tailored to a specific health system would eventually lead to improved screening guidelines and reminders for women at risk to get checked in a timely manner,” he notes.

Related Articles

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

Ad